| Oct 31 |
Amneal Pharmaceuticals (NASDAQ:AMRX) grows 3.0% this week, taking five-year gains to 211%
|
| Oct 21 |
Amneal gets FDA nod for NDA of its neuromuscular disorder treatment
|
| Oct 21 |
Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets
|
| Oct 9 |
Amneal Pharmaceuticals Inc (AMRX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
| Oct 8 |
Amneal to Report Third Quarter 2024 Results on November 8, 2024
|
| Oct 1 |
Amneal and Metsera collaborate to supply obesity and metabolic disease medicines
|
| Oct 1 |
Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases
|
| Sep 23 |
Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease
|
| Sep 6 |
Amneal raised to neutral by J.P. Morgan amid improved growth
|
| Sep 6 |
Organon downgraded, Amneal upgraded as J.P. Morgan reviews specialty pharma
|
